Unicycive therapeutics.

Find the latest SEC Filings data for Unicycive Therapeutics, Inc. Common Stock (UNCY) at Nasdaq.com.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...A Brief History of Unicycive Therapeutics, Inc. (UNCY) Unicycive Therapeutics, Inc. (UNCY) is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for various diseases and conditions. The company was founded in 2015 and is headquartered in San Diego, California.Mar 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...

About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...

Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of. As of. December 31, June 30, 2020. 2021 (unaudited) Assets. Current assets: Cash $-$ 1. Prepaid related party service fee-38. Deferred offering costs. 200. 864. Prepaid expenses and other current assets. 4. 10. Total current assets. 204 ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

About Unicycive Therapeutics, Inc. Unicycive is focused on two kidney diseases with large unmet medical needs. We are developing Renazorb, an investigational phosphate binding agent using ...18 Jul 2022 ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. ... SOURCE: Unicycive Therapeutics, Inc.Unicycive Therapeutics, Inc. employs a comprehensive promotion strategy that integrates the details of its products, pricing, and placement. The company carefully constructs its promotional message to convey the unique value proposition of its therapies to potential consumers. This message is designed to educate and persuade individuals about ...About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, lanthanum dioxycarbonate (LDC), is a novel ...Mar 8, 2023 · Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ...

Get the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of . As of . December 31, September 30, 2022 . 2023 (Unaudited) Assets

Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022) Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net ...Investors - Unicycive. [WE DO NOT CONTROL THIS SECTION OF THE SITE. WE WILL CONNECT WITH THE THIRD PARTY BUT MAY NEED TO CREATE THE HEADER IMAGE. THIS COULD BE A MAGNIFYING GLASS MADE OUT OF DOTS.] [WE DO NOT CONTROL THIS SECTION OF THE SITE.0. As of December 4, 2023, Unicycive Therapeutics (NASDAQ: UNCY) has received positive analyst coverage and recommendations. Bruce Jackson from Benchmark has …RedChip Companies will air a new interview with Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, on ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, RENAZORB (lanthanum dioxycarbonate), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia.View the latest Unicycive Therapeutics Inc. (UNCY) stock price, news, historical charts, analyst ratings and financial information from WSJ.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...

Nov 11, 2021 · Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of. As of. December 31, September 30, 2020. 2021 (unaudited) Assets. Current assets: Cash ... Unicycive Therapeutics level 2 order book with share price and UNCY stock charts. Free real-time prices, and the most active stock market forums. Unicycive Therapeutics (UNCY) stock price, charts, trades & the US's most popular discussion forums.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.Unicycive Therapeutics level 2 order book with share price and UNCY stock charts. Free real-time prices, and the most active stock market forums. Unicycive Therapeutics (UNCY) stock price, charts, trades & the US's most popular discussion forums.Events & Presentations. IR Calendar · Presentations. Oct 4, 2023. October 2023 Corporate Presentation. Oct 3, 2022 ...

Unicycive Therapeutics, Inc. 4300 El Camino Real Suite 210 Los Altos, CA 94022 United States 650 351 4495 https://unicycive.com Sector(s) : Healthcare Industry : Biotechnology Full Time Employees : 12

Unicycive Therapeutics Stock Performance. Shares of Unicycive Therapeutics stock opened at $0.52 on Monday. Unicycive Therapeutics has a 52-week low of $0.40 and a 52-week high of $2.87. The stock has a market capitalization of $18.07 million, a price-to-earnings ratio of -0.30 and a beta of 2.64.About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.Rhythmic activities are a series of movements in which individuals can take part during any steady and prominent beat. Professionals use these activities as therapeutic treatments for those who suffer from dementia.Unicycive Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for ...Aarvik Therapeutics is pursuing exciting molecules with an improved therapeutic index for several oncology targets by combining novel modular antibody platforms with multiple target mechanisms. Aarvik antibody platforms are readily manufacturable, scalable and versatile, and offer unlimited potential through modular design. ...Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS ...Get the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Mar 8, 2023 · Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ...

Lihat chart Unicycive Therapeutics, Inc. live untuk melacak pergerakan harga sahamnya. Temukan prediksi pasar, berita finansial dan pasar dari UNCY.

About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy.6 Mar 2023 ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel ...13 Jul, 2021, 08:30 ET. LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.Unicycive Therapeutics (NASDAQ:UNCY) has filed to raise $25 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing treatments for various kidney ...Prelude Therapeutics is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, small molecule therapies that precisely target the key drivers of cancer cell growth and resistance. With our core competencies in cancer biology, medicinal chemistry, and drug development, we are rapidly translating our …Dec 1, 2023 · Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. Unicycive Therapeutics (UNCY) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Unicycive Therapeutics today and set a price target of $4.50. The company’s shares closed last Wednesday ...

(Note: Unicycive Therapeutics priced its IPO on July 12, 2021, by slightly increasing the number of units to 5 million, up from 4.55 million in the prospectus, at $5 – the low end of …LOS ALTOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...Dec 9, 2022 · RedChip Companies will air a new interview with Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, on ... Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of. As of. December 31, September 30, 2020. 2021 (unaudited) Assets. Current assets: Cash $-$ 18,011. Prepaid related party service fee-58. Deferred offering costs. 200-Prepaid expenses and other current assets. 4. 1,713. Total current assets ...Instagram:https://instagram. best mortgages for self employedmetlife veteran dentalaccenture competitorsjnj spinoff LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). hydrogen companies stockesurance motorcycle Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...About UNCY. unicycive therapeutics is passionate about treating kidney diseases with significant unmet medical needs. A list of the latest Unicycive Therapeutics Inc News - UNCY Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions. best automation companies About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...